Literature DB >> 8761562

The epidemiology of malaria in a Karen population on the western border of Thailand.

C Luxemburger1, K L Thwai, N J White, H K Webster, D E Kyle, L Maelankirri, T Chongsuphajaisiddhi, F Nosten.   

Abstract

From November 1991 to November 1992 a prospective, descriptive study of malaria epidemiology was conducted in a Karen population on the western border of Thailand. Two study groups were selected at random and more than 80% of the subjects were followed for one year. In Group 1, comprising 249 schoolchildren (aged 4-15 years), daily surveillance for illness was combined with fortnightly malaria surveys. These children experienced 1.5 parasitaemic infections per child-year (95% confidence interval [CI] 1.3-1.7), of which 68% (193/285) were symptomatic (Plasmodium falciparum 84%, P. vivax 57%). The estimated pyrogenic densities were 1460/microL for P. falciparum and 181/microL for P. vivax. In Group 2, comprising subjects of all age from 428 households, malaria was diagnosed during two-monthly surveys, at weekly home visits, and otherwise by passive case detection. Malaria and splenomegaly prevalence rates were low in all age groups (spleen index 2-9%; P. falciparum prevalence rate 1-4%; P. vivax 1-6%). Group 2 subjects had 1.0 infections per person-year (95% CI 0.9-1.1), most of which were symptomatic (312/357; 87%). Malaria infections clustered in households. Overall, P. vivax caused 53% and P. falciparum 37% of the infections (10% were mixed), but whereas P. vivax was most common in young children, with a decline in incidence with increasing age, P. falciparum incidence rates rose with age to a peak incidence between 20 and 29 years, although the risk of developing a severe malaria decreased with increasing age. There was no death from malaria during the study. P. falciparum infections were more common in males, subjects with a history of malaria before the study, and in those who had travelled outside their village. These findings suggest a higher transmission rate for P. vivax than P. falciparum, although adults still suffered symptomatic malaria due to both species. The 2 malaria parasites found in this area contribute approximately 50% of infections each, but their clinical epidemiology is very different.

Entities:  

Mesh:

Year:  1996        PMID: 8761562     DOI: 10.1016/s0035-9203(96)90102-9

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  93 in total

1.  Oral artesunate dose-response relationship in acute falciparum malaria.

Authors:  Brian J Angus; Itaporn Thaiaporn; Kenechanh Chanthapadith; Yupin Suputtamongkol; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 2.  Why do we need to know more about mixed Plasmodium species infections in humans?

Authors:  Peter A Zimmerman; Rajeev K Mehlotra; Laurin J Kasehagen; James W Kazura
Journal:  Trends Parasitol       Date:  2004-09

3.  Clinical features of children hospitalized with malaria--a study from Bikaner, northwest India.

Authors:  Dhanpat Kumar Kochar; Gajanand Singh Tanwar; Poonam Chand Khatri; Sanjay Kumar Kochar; Ghanshyam Singh Sengar; Anjana Gupta; Abhishek Kochar; Sheetal Middha; Jyoti Acharya; Vishal Saxena; Deepak Pakalapati; Shilpi Garg; Ashish Das
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

4.  Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay.

Authors:  Edgie-Mark A Co; Richard A Dennull; Drew D Reinbold; Norman C Waters; Jacob D Johnson
Journal:  Antimicrob Agents Chemother       Date:  2009-04-06       Impact factor: 5.191

5.  Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria.

Authors:  Ric N Price; Anne-Catrin Uhlemann; Michele van Vugt; Al Brockman; Robert Hutagalung; Shalini Nair; Denae Nash; Pratap Singhasivanon; Tim J C Anderson; Sanjeev Krishna; Nicholas J White; François Nosten
Journal:  Clin Infect Dis       Date:  2006-04-26       Impact factor: 9.079

6.  Interspecific competition during transmission of two sympatric malaria parasite species to the mosquito vector.

Authors:  Rick E L Paul; Van Anh Ton Nu; Antoniana U Krettli; Paul T Brey
Journal:  Proc Biol Sci       Date:  2002-12-22       Impact factor: 5.349

7.  Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand.

Authors:  Udomsak Silachamroon; Srivicha Krudsood; Sombat Treeprasertsuk; Polrat Wilairatana; Kobsiri Chalearmrult; Hla Yin Mint; Pannamas Maneekan; Nicholas J White; Victor R Gourdeuk; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Am J Trop Med Hyg       Date:  2003-07       Impact factor: 2.345

8.  Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children.

Authors:  Enmoore Lin; Benson Kiniboro; Laurie Gray; Stuart Dobbie; Leanne Robinson; Annemarie Laumaea; Sonja Schöpflin; Danielle Stanisic; Inoni Betuela; Melinda Blood-Zikursh; Peter Siba; Ingrid Felger; Louis Schofield; Peter Zimmerman; Ivo Mueller
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

9.  Effects of mefloquine and artesunate mefloquine on the emergence, clearance and sex ratio of Plasmodium falciparum gametocytes in malarious children.

Authors:  Akintunde Sowunmi; Oluchi O Nkogho; Titilope M Okuboyejo; Grace O Gbotosho; Christian T Happi; Elsie O Adewoye
Journal:  Malar J       Date:  2009-12-16       Impact factor: 2.979

10.  The effect of varying analytical methods on estimates of anti-malarial clinical efficacy.

Authors:  Wendy J Verret; Grant Dorsey; Francois Nosten; Ric N Price
Journal:  Malar J       Date:  2009-04-22       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.